![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 07, 2014 1:04:23 PM
Senior Biotech analyst, Jason Napodano updated his report on DARA BioSciences, Inc. (DARA). In the report Jason details the specialty pharmaceutical company’s fourth quarter and full year financial results. Jason goes on to highlight insights from his meeting with management while attending the annual JP Morgan Healthcare Conference, as well as the parallel Biotech showcase and OneMedForum Conferences. Jason maintains his ‘Buy’ rating and $1.50 target price in this latest report.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM